AnaptysBio completes $40M Series D; Piqur raises $19M to back cancer drug R&D;

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: Chatted a bit with Immunocore's CEO, also chairman of MedCity, about global/UK #biotech $$$. Story | Follow @JohnCFierce

> San Diego-based AnaptysBio wrapped an oversubscribed $40M Series D financing round. Participants include BVF Partners L.P., BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors. The cash will fuel work on AnaptysBio's anti-IL-33 and anti-IL-36 receptor antibody programs through Phase II. "The proceeds of this financing provide AnaptysBio with the financial strength to potentially demonstrate efficacy of our anti-IL-33 program in severe adult asthma and peanut allergy patients, while also advancing our anti-IL-36 receptor program to proof-of-concept in generalized pustular psoriasis," said CEO Hamza Suria. Release

> Switzerland's Piqur Therapeutics just raised $19 million for its cancer drug R&D specializing in PI3K and mTOR inhibition. The biotech has raised a total of $60 million and is pushing its lead therapy, PQR309, through mid-stage tests. Versant Ventures joined a syndicate behind the A2 round. Release

> Ewing, NJ-based Celator Pharmaceuticals has begun enrolling patients in a Phase II clinical study evaluating CPX-351 (cyatarabine:daunorubicin) Liposome Injection as a treatment for patients with newly diagnosed Acute Myeloid Leukemia. Release

Medical Device News

@FierceMedDev: ICYMI: Courtagen reels in $20M for genetic pediatric neurology disorder tests. Story  | Follow @FierceMedDev

@EmilyWFierce: Boom in specialty pharma business draws questions from consumers, lawmakers and patient advocates. NYT story | Follow @EmilyWFierce

> Alere keeps diagnostics ball rolling with new deals and quick strep test win. News

> Survey: Docs expect HeartWare's blood pump to get expanded indication from FDA despite worrying trial data. More

Pharma News

@FiercePharma: FDA may tap $GOOG to beef up drug-safety monitoring. Story | Follow @FiercePharma

@EricPFierce: Gallant Pharma owner notified in jail by #FDA he is disbarred for life from the pharma industry. Item | Follow @EricPFierce

@CarlyHFierce: Dont you dare think for a second that I passed up the chance to discuss the $GSK wolf grandma on @FierceBiotech Radio. Listen | Follow @CarlyHFierce

>Endo whistleblower nabs $33.6M from feds for 'extraordinary' work in FCA suit. More

> Sanofi says sweeping management revamp won't come with job cuts. Story

Vaccines News

> GSK, bioCSL to increase flu vaccine deliveries to U.S. More

> Reuters: WHO, EMA likely to approve GlaxoSmithKline's malaria vaccine despite challenges. News

> GSK and J&J/Bavarian Nordic take Ebola candidates to Senegal, Europe. More

> Expect vaccines market to swell to $40B by 2020: Tufts CSDD. Article

> EMA to again place HPV vaccines under its safety lens. Story

CRO News

> Icon and Covance bet on diagnostics with a pair of cancer deals. More

> Aptuit scales up its production prowess for Phase III trials. News

> Frontage buys into biometrics with BDM deal. Report

> Under new ownership, Synexus expands across Europe. Story

> WuXi bets $50M on a new venture fund and eyes $200M more. Article

Pharma Manufacturing News

> GSK ramps up flu vax production after problems last year. News

> American Health Packaging pulls thousands of Wockhardt-made products from the market. Story

> Mylan issues third reminder that 'lifesaving' syringes are being recalled. More

> J&J expects Fort Washington, PA, consumer plant to be back on line soon. Story

> Pfizer announces it will shutter India plant, echoing same news from Sandoz. Article

Pharma Asia News

> India's biopharma woes grow with FDA Emcure plant ban. More

> Japan's Takeda files ixazomib NDA for relapsed multiple myeloma. Report

> WuXi Healthcare Ventures plucks $50M from WuXi PharmaTech as anchor for second fund. Article

> Price controls fail to improve poor people's access to medicines in India, IMS report says. Story

> CFDA eyes new Shanghai evaluation center to speed drug approvals. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.